Oruka Therapeutics, Inc. (ORKA)
96.02
+0.21
(+0.22%)
USD |
NASDAQ |
Oct 28, 16:00
96.02
0.00 (0.00%)
After-Hours: 16:52
Oruka Therapeutics Enterprise Value : 4.983B for Oct. 27, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 27, 2026 | 4.983B |
| October 26, 2026 | 4.648B |
| October 23, 2026 | 4.027B |
| October 22, 2026 | 4.088B |
| October 21, 2026 | 4.013B |
| October 20, 2026 | 3.962B |
| October 19, 2026 | 3.680B |
| October 16, 2026 | 3.525B |
| October 15, 2026 | 3.643B |
| October 14, 2026 | 3.815B |
| October 13, 2026 | 3.907B |
| October 12, 2026 | 4.039B |
| October 09, 2026 | 4.146B |
| October 08, 2026 | 3.851B |
| October 07, 2026 | 3.987B |
| October 06, 2026 | 4.028B |
| October 05, 2026 | 4.285B |
| October 02, 2026 | 4.294B |
| October 01, 2026 | 4.226B |
| September 30, 2026 | 4.218B |
| September 29, 2026 | 4.149B |
| September 28, 2026 | 4.273B |
| September 25, 2026 | 4.290B |
| September 24, 2026 | 4.353B |
| September 23, 2026 | 4.624B |
| Date | Value |
|---|---|
| September 22, 2026 | 4.906B |
| September 21, 2026 | 4.835B |
| September 18, 2026 | 4.931B |
| September 17, 2026 | 5.100B |
| September 16, 2026 | 4.845B |
| September 15, 2026 | 4.763B |
| September 14, 2026 | 4.990B |
| September 11, 2026 | 4.774B |
| September 10, 2026 | 4.729B |
| September 09, 2026 | 4.720B |
| September 08, 2026 | 4.891B |
| September 04, 2026 | 4.781B |
| September 03, 2026 | 4.689B |
| September 02, 2026 | 4.728B |
| September 01, 2026 | 4.757B |
| August 31, 2026 | 4.788B |
| August 28, 2026 | 4.698B |
| August 27, 2026 | 5.028B |
| August 26, 2026 | 5.205B |
| August 25, 2026 | 5.350B |
| August 24, 2026 | 5.387B |
| August 21, 2026 | 5.725B |
| August 20, 2026 | 5.536B |
| August 19, 2026 | 5.831B |
| August 18, 2026 | 6.038B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Tenax Therapeutics, Inc. | -63.02M |
| Exicure, Inc. | 5.103M |
| Century Therapeutics, Inc. | 180.75M |
| Absci Corp. | 1.616B |
| Celularity, Inc. | 92.39M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -41.21M |
| Total Expenses (Quarterly) | 41.21M |
| EPS Diluted (Quarterly) | -0.6554 |
| Earnings Yield | -2.56% |
| Normalized Earnings Yield | -2.565 |